Rockefeller U Nets at Least $7M from Ligand after Settling IP Row over Blood Disease Rx

The settlement terminates a licensing agreement signed between Rockefeller and Ligand in 1992 related to patents and know-how surrounding peptidyl hormone-mediated gene expression technology discovered primarily by a Rockefeller scientist.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.